van Rooijen & Partners is proud to inform: <<
Press release.
Affectis Pharmaceuticals AG Announces Target Validation Collaboration with Organon
Munich, Germany -- Affectis Pharmaceuticals AG and Organon, the human healthcare business unit of Akzo Nobel, have entered into a collaboration by which Affectis will apply its pioneering target validation technology and its exclusive preclinical models for the validation of Organon’s gene targets involved in depression and anxiety.
Today, one of the major challenges in developing optimised drugs against affective disorders is the limited availability of suitable preclinical models and sufficient expertise in selecting promising targets and leads as well as their preclinical development. Affectis´ team has more than 10 years experience in developing, performing and interpreting behavioural assays and preclinical models of diseases such as depression and anxiety.
"We are very glad to bring our unique expertise into the partnership with Organon, a global leader in the creation of innovative prescription medicines for mental health," Dr Herbert Stadler, Chief Executive Officer of Affectis Pharmaceuticals AG, comments. "Since the foundation of Affectis in late 2002, we have attracted several internationally renowned partners and continuously strengthened our position as a leading research and development organisation in the field of affective disorders."
"We are delighted to work with Affectis in the further validation of some exciting new targets with potential for the development of novel treatments for CNS diseases." Dr Chris Hill, Organon's Vice-President Research in Scotland, comments.
Contact for Affectis Pharmaceuticals AG:
Dr Herbert Stadler
Chief Executive Officer
Kraepelinstrasse 2 D-80804 Munich, Germany
Tel.: +49 (0)89 - 306 22 - 653
Fax: +49 (0)89 - 306 22 - 370
Email: stadler@affectis.com
www.affectis.com